Market revenue in 2023 | USD 24.0 million |
Market revenue in 2030 | USD 43.5 million |
Growth rate | 8.8% (CAGR from 2023 to 2030) |
Largest segment | Surgery |
Fastest growing segment | Intralesional injections |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Radiotherapy (RT), Intralesional injections, Intravenous Medications, Chemical peeling treatment, Surgery, Topical chemotherapy, Oral Medications |
Key market players worldwide | Bausch Health Companies Inc, Almirall SA, Genentech, Novartis AG ADR, Regeneron Pharmaceuticals Inc, Dr Reddy's Laboratories Ltd ADR, Taro Pharmaceuticals, Accord Healthcare |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to basal cell carcinoma treatment market will help companies and investors design strategic landscapes.
Surgery was the largest segment with a revenue share of 35.83% in 2023. Horizon Databook has segmented the India basal cell carcinoma treatment market based on radiotherapy (rt), intralesional injections, intravenous medications, chemical peeling treatment, surgery, topical chemotherapy, oral medications covering the revenue growth of each sub-segment from 2018 to 2030.
Promoting cancer prevention and early detection is expected to boost the diagnosis of various cancers, including BCC. Early detection is critical for effective treatment and management of BCC, the most common type of skin cancer.
As more people become aware of the symptoms and the importance of early screening, the number of diagnosed cases is expected to rise. For instance, in March 2023, Roche Diagnostics India entered into an agreement with the Cancer Awareness Prevention and Early Detection Trust (CAPED).
To promote cancer prevention, awareness, and early detection. Similarly, in September 2022, AstraZeneca India and the CAPED Trust launched the Ganga Godavari Cancer Screening Program to reduce India's cancer burden.
Horizon Databook provides a detailed overview of country-level data and insights on the India basal cell carcinoma treatment market , including forecasts for subscribers. This country databook contains high-level insights into India basal cell carcinoma treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account